{"id":"W2117496910","doi":"10.1517/13543776.18.9.975","title":"Structural biology in the battle against BCR-Abl","year":2008,"lang":"en","type":"article","venue":"Expert Opinion on Therapeutic Patents","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University","funders":"Vertex Pharmaceuticals; Bristol-Myers Squibb; Boehringer Ingelheim","keywords":"Imatinib; Chronic myelogenous leukemia; Tyrosine kinase; Drug resistance; ABL; Tyrosine-kinase inhibitor; Drug; Cancer research; Pharmacology; Medicine; Leukemia; Biology; Cancer; Immunology; Myeloid leukemia; Internal medicine; Receptor; Genetics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005945479,0.0004563235,0.0005326096,0.0004397891,0.0005090255,0.001160321,0.0005765725,0.00124966,0.003998671],"category_scores_gemma":[0.0003430468,0.0001923362,0.0002690715,0.0005162907,0.001315003,0.002541868,0.0007265419,0.001868508,0.001787371],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00110865,"about_ca_system_score_gemma":0.0007575766,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003625638,"about_ca_topic_score_gemma":0.0005537503,"domain_scores_codex":[0.9998193,0.00004755914,0.000006994919,0.0000231224,0.00006283012,0.00004013431],"domain_scores_gemma":[0.9998717,0.00004775689,0.00002280798,0.000007438933,0.00002255736,0.00002771094],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00049046,0.0003328352,0.0006553982,0.00297578,0.00008680605,0.001026035,0.0005273402,0.01047913,0.2212748,0.3547658,0.03074126,0.3766444],"study_design_scores_gemma":[0.0002625815,0.001135495,0.0007609572,0.0003899719,0.00006930107,0.001933816,0.0004359239,0.004270314,0.06861318,0.1660326,0.75604,0.0000559695],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.1127837,0.6472512,0.03328237,0.1045374,0.003135408,0.0001880402,0.0002921418,0.0005840674,0.09794561],"genre_scores_gemma":[0.4442028,0.4986894,0.01889162,0.01533066,0.001507127,0.0001204278,0.0002754836,0.00008645518,0.02089611],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.003998671,"threshold_uncertainty_score":0.01337689,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1027041500105693,"score_gpt":0.3470829673624465,"score_spread":0.2443788173518772,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}